The Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The castrate resistant prostate cancer market comprises drugs used for treatment of prostate cancer that has spread to other parts of the body even after the removal of testicles or after receiving hormone therapy. Some of the commonly used drugs are abiraterone, enzalutamide, docetaxel, cabazitaxel, sipuleucel-T, and radium-223. These drugs help in controlling the growth and spread of cancer cells and relieve symptoms like bone pain.
The castrate resistant prostate cancer market is witnessing high growth owing to increased incidences of castrate resistant prostate cancer. According to Cancer Research UK, about 4,800 cases of castrate resistant prostate cancer are reported in UK annually. Rising awareness about early detection and treatment options is also leading to increased diagnosis rates. Growing geriatric population is another major factor as prostate cancer is predominantly found in men aged above 65 years. Moreover, ongoing research & development activities for development of novel therapeutics and combination therapies will further aid market growth over the forecast period. For instance, in 2021, Janssen received FDA approval for Erleada (apalutamide) in combination with androgen deprivation therapy for treatment of metastatic castrate-sensitive prostate cancer.
The Global Castrate Resistant Prostate Cancer Market Share is expected to witness high growth at a CAGR of 8.2% over the forecast period, due to increasing prevalence of prostate cancer among aging population and availability of advanced treatment alternatives.
Regionally, North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to growing prostate cancer incidence, favorable reimbursement policies, and healthcare infrastructure in the region.
Key players operating in the Castrate Resistant Prostate Cancer market are Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
Read more
https://healthcarelatesteditionnews.blogspot.com/2023/11/the-castrate-resistant-prostate-cancer.html
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian